Based on the primary site predicted by the combination of clinical investigations, clinicopathological data and molecular testing, TRPS1 expression was observed in 11 of 13 predicted breast carcinoma (84.6%), INSM1 expression was observed in all 3 predicted neuroendocrine neoplasms, and P16/HPV positivity was observed in all 4 predicted cervical carcinomas. This evidence concerns the gene INSM1 and neuroendocrine neoplasm.